Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Entereg RiskMAP’s Ability To Prevent Heart Attacks Gets Advisory Panel Review

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA questions the risk-management plan proposed by GlaxoSmithKline/Adolor to address myocardial infarctions reported in Phase III studies for alvimopan in GI indication.
Advertisement

Related Content

GSK/Adolor's Entereg Eligible For Approval, But Lacks Proper Risk Management Plan, Advisory Panel Says
GSK/Adolor's Entereg Eligible For Approval, But Lacks Proper Risk Management Plan, Advisory Panel Says
GSK/Adolor Entereg “Approvable” Pending CV Risk Data
GSK/Adolor Entereg “Approvable” Pending CV Risk Data
Entereg Fails Phase III Trial; Adolor/GSK To Re-Examine Placebo Effect

Topics

Advertisement
UsernamePublicRestriction

Register

PS066761

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel